(CGVHD), older age, use of methotrexate (MTX) as prophylaxis for GVHD and low levels of serum immunoglobulin (Ig). 5, 6 Classical management of these patients To describe clinical outcome with first line immunosuppression therapy for obstructive airways disease includes bronchodilators (aerosolised ␤-agonists), antiinfectious prophylaxis, Igs replacement, and immunosup-(OAD) after allogeneic BMT, we have retrospectively examined 20 long-term survivors affected by OAD. All pressive agents such as prednisone (PRD), AZT or CsA. Despite aggressive treatment, the mortality rate is over 50% patients had normal pulmonary function test (PFTs) before BMT. OAD was defined as FEV1 less than 80%, (ranging from 21 to 100%), in most published series, 7,8 significantly higher than in comparable cohorts without OAD. FER less than 80%, maximum midexpiratory flow rate of 50% vital capacity (MMFR) less than 65%, or
Study population characteristics
Criteria for diagnosis of OAD

The diagnosis of OAD was based on clinical symptoms and
Category
Unaffected n = 205 OAD n = 20 pulmonary function testing. Criteria were defined according to previous studies. 9 Patients were diagnosed with OAD Age mean ± s.d. 22.6 ± 11.6 24.2 ± 11.7
when they met the following criteria: (1) (7) 1 (5) vital capacity less than 65% of that predicted; or residual Prophylaxis GVHD (%) volume greater than 120% of that predicted.
CsA + MTX 56 (27) 2 (10) MTX alone 48 (23) 2 (10) Acute GHVD (I-IV) (%) 108 (53) 16 (80)
Response criteria
Chronic GHVD (%) 50 (24) 17 (85) IV IGS (%) 70 (34) 8 (40) Frequency of follow-up was determined by physician assessment of clinical need. Time under treatment was established considering all CGVHD manifestations. The response to treatment for OAD has been analysed regardless of CGVHD evolution. We followed the criteria below, in accordance with previous studies of CGVHD treat-12 Gy or single dose 9 Gy with lung shielding) or ment. 10,11 A complete response was classified as complete busulphan 16 mg/kg).
disappearance of clinical manifestation with at least two objective parameters (FEV1, MMFR or RV) within the nor-AGVHD prophylaxis: This consisted of CsA 3 mg/kg/day mal range. A partial response included symptom improvei.v. divided into two doses and starting on day −1. Methoment as well as improvement in PFTs, without reaching trexate prophylaxis when given with CsA was administered normal values. Patients were considered to have no as 15 mg/m 2 i.v. on day 1, and 10 mg/m 2 on days 3, 6 and response if OAD progressed or failed to improve after 3 11 after transplantation. Patients who received methotrexate months of immunosuppressive treatment. without CsA as GVHD prophylaxis received the same schedule as described above and 10 mg/m 2 weekly until day 100 after BMT. Staging of acute and chronic GVHD was Statistical analysis performed according to criteria described elsewhere.
Continuous variables were compared using Student's t-test, After 1992, intravenous Ig (0.5 g/kg) was administered and categorical variables were compared using 2 statistics. to randomly selected patients, every 2 weeks from day 0
The significance of prognostic factors in the development until day +90 and then monthly until day +365. Levels of of OAD was asssessed on a multivariate basis using the IgA and IgG were measured by immuno assay monthly score test from the Cox proportional hazards model. Surafter BMT.
vival was analysed by the Kaplan-Meier method with subgroups compared by the log-rank test. Non-parametric tests (Kruskal-Wallis) were used to study the relationship Pulmonary function tests between patterns of response and pre-treatment values of PFTs, and to analyse changes in PFT results with different All patients underwent pulmonary evaluation during the 14 immunosuppression modalities. days before BMT with a clinical assessment, chest radiograph and a complete set of pulmonary function tests (PFTs).
Results PFTs were performed with standard laboratory equipment. Flow-volume curves were generated using a wet spirometer (Jaeger 3.30 MasterLab System, Wüerzburg, Twenty patients (8.9%) were diagnosed with OAD from 225 patients who survived more than 3 months after BMT. Germany) to measure the forced expiratory volume in 1 s (FEV1), vital capacity (VC), forced expiratory ratio (FER:
Mean characteristics of these patients are summarised in Table 2 . Mean follow-up was 65 months (range 15-142). FEV1 over FVC) and maximum mid-expiratory flow rate (MMFR). Total lung capacity (TLC) and residual volume PFTs were performed periodically with clinical and functional (Karnofsky index) assessment. At diagnosis, chest (RV) were determined by the body plethysmographic technique and also the single-breath helium dilution technique radiographs were normal in 16 (80%) patients and four showed patchy infiltrates. High resolution computed tomofor measuring carbon monoxide diffusion capacity (DLCO) (Vitalograph Ohmeda, C Schatman, Hamburg, Germany). graphy was performed on five patients and showed segmen- 6-12 6 (30) statistical differences between the two groups (P = 0.1). results are described in Table 3 . Time of onset was quite early (Ͻ6 months) in four and degree of OAD at diagnosis was severe in two. Mean value of MMFR prior to treatment was 30% and mean value of RV was 176%. Only one tal or subsegmental bronchial dilatation. Bronchoalveolar patient in this group died due to leukaemic relapse. We lavage and transbronchial biopsy were performed in three observed that the maximum values of at least two PFTs patients who showed non-specific inflammatory changes.
parameters reached under treatment are achieved quite early All patients at diagnosis were started or continued on (mean value 6 months, range 2-9 months) ( Figure 1 ). corticosteroid treatment; cotrimoxazol or ciprofloxacine daily, Ig i.v. replacement (0.5 g/kg/day), penicillin retard
No response: Eight patients (40%) did not respond to i.m. monthly, aerosolised ␤-agonist, and eufiline were immunosuppression. Characteristics are summarized in given as supportive care. Four patients needed continuous Table 4 . FEV1 was lower than 30% of the predicted value oxygen therapy. AZT was used as first-line immunoin three of them and the time of onset was early in two. suppression (eight patients) until 1991 when it was replaced Mean value MMFR prior to treatment was 14% and RV by CYA (eight patients). Second-line treatment in patients was 356%. In this group, three patients died although only with partial or no response included CsA in patients preone death was due to respiratory failure. We observed that viously treated with AZT, and thalidomide 12 in two patients FEV1 and MMFR do not improve, but in patients with a who had received CsA. Six patients died (30%), four due long-term follow-up, RV tends to normalise (Figure 2 ). to leukaemia relapse and two to respiratory failure. Nonfatal non-infectious complications included subcutaneous emphysema (three patients), pneumothorax (two patients),
Partial response: Six patients (30%) were included in this group. Characteristics are summarized in Table 5 . One tracheal mucoepidermoid carcinoma (one patient) and aseptic necrosis of the femoral head (one patient).
patient died due to OAD and one due to leukaemic relapse. MMFR mean value before treatment was 21.5% and RV Risk factors for developing OAD were evaluated in this study. We did not find a statistical correlation with age, mean value was 155%. Maximum values of at least two PFTs parameters were achieved within the first 10 months sex, diagnosis, prior chemotherapy toxic to the lung or conditioning regimen. In our series, CGVHD was the major of treatment, ranging from 8 to 14 months ( Figure 3) . We analysed pre-treatment variables correlated with subrisk factor and only three patients developed OAD with no signs of CGVHD (85 vs 24.4%, P Ͻ 0.001, odds ratio 5.04, sequent response. Statistical analysis of these three categories showed that there were no significant differences in age, confidence interval: 1.7-14.3). Patients who developed acute GVHD (of all grades) are also more likely to develop Karnofsky index or time of onset after BMT. Among PFTs results, we found no statistical association with FEV1 or OAD (80 vs 52.7%, P = 0.019, odds ratio 2.3, confidence interval: 1.2-11.1). The use of MTX alone as AGVHD FER pre-treatment values. However, we did find statistical differences in RV pre-treatment values: 356, 155 and 176% prophylaxis was not a risk factor when compared with the CYA and MTX schedule (Table 1 ). There was an increased for no, partial and complete response groups, respectively (P = 0.009) and MMFR pre-treatment values: 14, 21.5 and incidence of OAD among patients receiving CYA alone as AGHVD prophylaxis, probably due to an increased inci-30%, respectively (P = 0.05). Grouping patients according to first-line immunosuppression modality (CsA n = 8, PDR dence of CGHVD. We found no statistical differences in serum IgA and IgG levels measured at 6, 12, 18 and 24 n = 4 and AZT n = 8) revealed no statistical differences in change of PFT from beginning to withdrawal (data not months after BMT, using the Student's t-test (data not shown).
shown). nition is highlighted by Clark et al 7 who found patients with an early onset and severe degree (FEV1 under 80%) to be a poor prognostic group wth a higher mortality rate. Likewise, Curtis et al 17 suggested that severe cases at diagnosis with an FEV1 lower than 50%, show progressive disease despite aggressive treatment. Categorisation of patients according to response criteria has allowed us to analyse all pre-treatment values in order to predict later outcome. In our series, age, time of onset, FEV1 and Karnofsky index do not seem to identify a responsive group. However, there are statistical differences in MMFR and RV among the three groups, suggesting that severe degrees of OAD measured by low MMFR values and high RV values (14 and 376% mean values, respectively in our series) could predict poor response to treatment. Altogether, these data suggest that early recognition of this syndrome could allow initiation of therapy at a potentially reversible stage.
Supportive care is essential in patients affected by OAD. General management including beta-agonists, euphlilyne and oxygen therapy is widely accepted. Our patients have undergone vigorous anti-infectious prophylaxis with oral ciprofloxacine, co-trimoxazole and penicillin i.m., as well as Ig replacement. These measures could be of great impor- (10% in our series). Although some studies have suggested an infectious agent or micro-aspiration mechanism, 18, 19 immunological damage is accepted as the etiological basis.
Discussion
This may be because of the undoubted association of OAD and CGVHD, the ability of lung epithelium to express class OAD due to bronchiolitis obliterans as the result of BMT II HLA and to generate alloreactivity in experimental modhas emerged as a very serious complication. Although the els, 20, 21 and the presence of similar disease in recipients of first description 3 was given in 1982, few advances have lung transplantation. 22 This approach supports the use of been made concerning pathogenic mechanism, differential immunosuppressive agents for these patients regardless of diagnosis and clinical management. The wide spectrum of other signs of CGVHD. Few studies have described clinical lung disease attributed to GVHD usually discloses heteroand functional response to treatment, probably because of geneous histopathologic findings on lung biopsy.
13,14 In short follow-ups or high mortality rates. Clark et al 7 failed addition, obstructive, restrictive and mixed patterns are to detect differences in treatment regimens, and Schultz et shown in PFTs, leading to confusing terminology. 15 Whereas al. 8 with a childhood series, suggested that any suppressive open lung biopsy remains a very aggressive procedure, therapy appears to result in a slight improvement. Our PFTs are often feasible and play an essential role in diagresults agree with these findings since we found no statistinosis of OAD. 16 FER under 80% has been used classically cal differences between the three therapy modalities measas a specific hallmark of OAD due to obliterative bronchiouring changes in PFT values over the treatment period. 
